ingrid030 schreef:
[quote=jacoba]
Leiden, The Netherlands, May 21, 2010. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) reports that it has received the Day 180 List of Outstanding Issues (LoOI) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Pharming submitted the Marketing Authorization Application (MAA) for Rhucin for the treatment of acute attacks of Hereditary Angioedema (HAE) to the European Medicines Agency in September 2009. The Company responded to the D120 List of Questions in March 2010. After review of the response, the CHMP has now summarized its outstanding questions in the Day 180 LoOI. Pharming plans to submit its response to these questions within the regular one month clock stop period. In line with the regulatory timetable, the CHMP will subsequently re ach its final opinion no later than Day 210. More information on this procedure can be found on
www.ema.europa.eu. “There are only a few minor issues left and we are confident that we will be able to provide our response quickly”, said Dr. Bruno Giannetti, Chief Operations Officer of Pharming.
[/quote]
met een slecht sentiment en dit nieuws kunnen we ons opmaken voor 23 cent, de eerste bestens staan al weer in de laat.